BAM
VRTX icon

Belpointe Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Belpointe Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.24M Sell
2,776
-1,404
-34% -$655K 0.05% 377
2025
Q4 		$1.9M Sell
4,180
-55
-1% -$23.7K 0.07% 236
2025
Q3 		$1.66M Buy
4,235
+455
+12% +$190K 0.06% 266
2025
Q2 		$1.68M Sell
3,780
-225
-6% -$104K 0.07% 233
2025
Q1 		$1.94M Buy
4,005
+2,784
+228% +$1.3M 0.1% 186
2024
Q4 		$605K Sell
1,221
-26
-2% -$12.1K 0.04% 466
2024
Q3 		$580K Buy
1,247
+145
+13% +$69.7K 0.03% 467
2024
Q2 		$517K Buy
1,102
+76
+7% +$33K 0.04% 449
2024
Q1 		$429K Buy
1,026
+297
+41% +$126K 0.03% 474
2023
Q4 		$297K Buy
729
+50
+7% +$18.5K 0.03% 524
2023
Q3 		$236K Sell
679
-240
-26% -$83.9K 0.02% 554
2023
Q2 		$323K Sell
919
-595
-39% -$200K 0.03% 423
2023
Q1 		$477K Sell
1,514
-3,351
-69% -$1.01M 0.03% 585
2022
Q4 		$1.4M Sell
4,865
-2,062
-30% -$628K 0.08% 242
2022
Q3 		$2.01M Buy
6,927
+1,593
+30% +$458K 0.14% 157
2022
Q2 		$1.5M Sell
5,334
-334
-6% -$89.4K 0.1% 215
2022
Q1 		$1.48M Sell
5,668
-310
-5% -$73.6K 0.09% 239
2021
Q4 		$1.29M Buy
5,978
+281
+5% +$54.6K 0.08% 252
2021
Q3 		$1.03M Buy
5,697
+258
+5% +$50.4K 0.07% 302
2021
Q2 		$1.1M Buy
5,439
+897
+20% +$188K 0.08% 272
2021
Q1 		$976K Buy
4,542
+3,449
+316% +$758K 0.08% 258
2020
Q4 		$258K Buy
1,093
+354
+48% +$81.2K 0.02% 620
2020
Q3 		$201K Sell
739
-1,259
-63% -$347K 0.02% 548
2020
Q2 		$580K Buy
1,998
+296
+17% +$80.3K 0.08% 269
2020
Q1 		$405K Sell
1,702
-1,164
-41% -$267K 0.07% 280
2019
Q4 		$628K Buy
+2,866
New +$580K 0.08% 276

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Belpointe Asset Management's VRTX Position: Q1 2026 in Review

Belpointe Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 34% in Q1 2026, selling an estimated $655K and leaving 2,776 shares worth $1.24M. The position accounts for 0.05% of the portfolio, ranked #377.

Belpointe Asset Management first reported a position in VRTX in Q4 2019 and has held it in 26 quarters since. The position peaked at $2.01M in Q3 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Belpointe Asset Management held 2,776 shares of Vertex Pharmaceuticals worth $1.24M as of Q1 2026.
  • Belpointe Asset Management sold 1,404 Vertex Pharmaceuticals shares in Q1 2026, an estimated $655K.
  • Vertex Pharmaceuticals made up 0.05% of Belpointe Asset Management's portfolio in Q1 2026, its #377 holding.
  • Belpointe Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • Belpointe Asset Management's Vertex Pharmaceuticals position peaked at $2.01M in Q3 2022.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Belpointe Asset Management's 13F filing for Q1 2026, filed 28 Apr 2026.